Jul 19, 2018

Bioxodes to present up-to-date preclinical data during the annual ISTH SSC meeting on Thursday 19 July 2018 in Dublin.

Poster presentation:

Abstract presentation number: PB503 - "Ir-CPI: an original inhibitor of thrombosis and thrombosis-associated with cancer"

Poster ISTH 2018.pdf

Oral presentation:

"Ir-CPI a New Potent Inhibitor of Thrombosis and Thrombosis Associated with Cancer"

Link: http://www.ssc2018.org/

Dublin, Ireland

Jul 19, 2018

Bioxodes has been invited based on its high-scoring abstract to give an oral presentation in the SCC Subcommittee on Hemostasis and Malignancy session

Oral presentation:

"Ir-CPI: an original inhibitor of thrombosis and thrombosis associated with cancer"

Link: http://www.ssc2018.org/

Dublin, Ireland

Jul 10, 2017

Bioxodes to present preclinical data for its main product, Ir-CPI, at ISTH 2017 annual congress.

Abstract Title: "Efficacy of a Novel Contact Pathway Inhibitor, Ir-CPI, on in vitro Clotting Induced by PCI Catheter Segment"

Link: http://www.isth2017.org/

Poster ISTH 2017.pdf

Berlin, Germany

May 1, 2016

Bioxodes to participate at the ISTH SCC 2016 annual congress.

Montpellier, France

Jun 1, 2015

Bioxodes to present preclinical data for its main product, Ir-CPI, at ISTH 2015 annual congress.

Abstract titles : 
“Efficacy of a novel contact pathway inhibitor, Ir-CPI, in an extracorporeal membrane oxygenator model” ECMO 2015.pdf
“Antithrombotic effects of Ir-CPI in an arterio-venous shunt model in the rabbit” AV-shunt 2015.pdf
“Evaluation of the effects of a novel contact pathway inhibitor, Ir-CPI, on in vitro platelet function and coagulation” Platelets 2015.pdf

Toronto, Canada